Search clinical trials for: nivolumab, ipilimumab

Total 1959 results

The Netherlands Cancer Institute
Bristol-Myers Squibb

Completed

Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma (INITIATE)

Malignant Pleural Mesothelioma

Netherlands
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Active, not recruiting

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

Mesothelioma

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (CheckMate 648)

Various Advanced Cancer

United States, Japan, Argentina, Australia, Austria, Brazil, Canada, Chile, China, Colombia, Czechia, Denmark, France, Hong Kong, Italy, Korea, Republic of, Mexico, Peru, Poland, Portugal, Romania, Russian Federation, Singapore, Spain, ... and more
Universita di Verona

Not yet recruiting

Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome (LUNGVIR)

HIV | HBV | Long COVID | NSCLC Stage IV | HCV

Italy
Yale University
Bristol-Myers Squibb

Active, not recruiting

Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy

Small Cell Lung Cancer

United States
Gritstone bio, Inc.
Bristol-Myers Squibb

Completed

A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens

Colorectal Cancer | Pancreatic Cancer | Non-Small Cell Lung Cancer | Solid Tumor | Shared Neoantigen-Positive Solid Tumors

United States
The Netherlands Cancer Institute
Bristol-Myers Squibb

Recruiting

Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer (NESCIO)

Renal Cell Carcinoma

United Kingdom, Netherlands
University of Texas Southwestern Medical Center

Completed

SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients (RADVAX)

Kidney Cancer | Kidney Cancer Metastatic | Kidney Cancer, Stage IV

United States
Prof. Dr. med. Dirk Schadendorf

Completed

Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED

Malignant Melanoma

Germany
Goethe University

Active, not recruiting

Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC

Metastatic Renal Cell Carcinoma

Spain, Netherlands, United Kingdom, France, Germany, Belgium, Czechia
Bristol-Myers Squibb

Terminated

A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer (CheckMate 74W)

Cancer, Hepatocellular

China, United States, Germany, Australia, Italy, Austria, Belgium, Czechia, France, Hong Kong, Japan, Korea, Republic of, Poland, Puerto Rico, Russian Federation, Singapore, Spain, Taiwan, Canada
Gritstone bio, Inc.
Bristol-Myers Squibb

Completed

A Study of a Personalized Neoantigen Cancer Vaccine

Colorectal Cancer | Non Small Cell Lung Cancer | Gastroesophageal Adenocarcinoma | Urothelial Carcinoma

United States, Australia
The Netherlands Cancer Institute

Completed

ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma (IMCISION)

Head and Neck Neoplasms | Immunotherapy

Netherlands
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915)

Melanoma

Belgium, Brazil, United States, Canada, Spain, Greece, France, United Kingdom, Australia, Italy, Austria, Switzerland, Germany, Israel, Russian Federation, Romania, Czechia, Poland, New Zealand
Celgene
NYU Langone Health; Syneos Health; Celerion; ApoCell, Inc.

Completed

Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab

Malignant Melanoma

United States
Patrick Wen, MD
Bristol-Myers Squibb

Active, not recruiting

Surgical Nivolumab And Ipilimumab For Recurrent GBM

Glioblastoma | Glioblastoma Multiforme | GBM | Grade IV Astrocytoma

United States
Bristol-Myers Squibb

Terminated

A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types (CheckMate 76U)

Tumor

Italy, United States, New Zealand
University of Utah
Bristol-Myers Squibb; Acrotech Biopharma Inc.

Withdrawn

Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation (BENEFIT)

Metastatic Adenocarcinoma
David Minor, MD
University of Chicago; Jefferson Medical College of Thomas Jefferson University and other collaborators

Active, not recruiting

Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases

Uveal Melanoma | Hepatic Metastases

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

Lung Cancer | Metastatic Cancer | Bladder Cancer | Renal Cancer | Melanoma Cancer | Head/Neck Cancers

United States
GERCOR - Multidisciplinary Oncology Cooperative...
Bristol-Myers Squibb

Active, not recruiting

iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab (NIPICOL)

Metastatic Cancer Colorectal

France
AIO-Studien-gGmbH
Bristol-Myers Squibb

Completed

A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck (OPTIM)

Carcinoma, Squamous Cell of Head and Neck | Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Germany
National Cancer Institute (NCI)

Recruiting

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Glioblastoma | Malignant Glioma | Gliosarcoma

United States
Dana-Farber Cancer Institute
Bristol-Myers Squibb

Recruiting

An Open-Label Phase II Study of Nivolumab in Adult Participants With Progessive/ Recurrent Meningioma

Meningiomas

United States
University Hospital, Strasbourg, France
Bristol-Myers Squibb

Completed

Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis (CRIRIN)

Melanoma (Skin)

France
Pfizer
Merck Sharpe & Dohme LLC

Recruiting

A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma (PORTSIDE)

Melanoma

Italy, Spain, Czechia, Germany, Slovakia, Poland, United Kingdom
GERCOR - Multidisciplinary Oncology Cooperative...
Bristol-Myers Squibb

Recruiting

Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. (NEONIPIGA)

Localized Oesogastric Adenocarcimona | MSI and or dMMR

France
Jason J. Luke, MD
Bristol-Myers Squibb

Terminated

Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma (QUAD01)

Melanoma

United States
Grupo Español Multidisciplinar de Melanoma
Bristol-Myers Squibb

Completed

Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma (GEM1402)

Uveal Melanoma

Spain
Vyriad, Inc.
Mayo Clinic

Recruiting

Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors

Solid Tumor | Non Small Cell Lung Cancer | Neuroendocrine Carcinoma

United States
Oslo University Hospital
Massachusetts General Hospital; Dana-Farber Cancer Institute; University Medical... and other collaborators

Active, not recruiting

Improved Therapy Response Assessment in Metastatic Brain Tumors (TREATMENT)

Brain Metastases

Norway
Novartis Pharmaceuticals

Completed

Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

Melanoma

United States
Universitair Ziekenhuis Brussel

Active, not recruiting

Intra-tumoral Ipilimumab Plus Intravenous Nivolumab Following the Resection of Recurrent Glioblastoma (GlitIpNi)

Glioblastoma

Belgium
Abramson Cancer Center at Penn Medicine

Recruiting

Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab

Melanoma | Melanoma Stage III

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma

Pleural Biphasic Mesothelioma | Pleural Sarcomatoid Mesothelioma

United States
Sheba Medical Center
Bristol-Myers Squibb; Checkmate Pharmaceuticals

Completed

Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer

Liver Metastases | Colorectal Neoplasms Malignant

Israel
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors

Pituitary | Pituitary Tumor | Pituitary Cancer | Pituitary Carcinoma

United States
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb

Completed

Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs

Advanced Stage Non-small Cell Lung Cancer

United States
Memorial Sloan Kettering Cancer Center
Pfizer

Recruiting

Axitinib and Nivolumab for the Treatment of Mucosal Melanoma

Mucosal Melanoma

United States
Amr Mohamed MD
Novatek Pharmaceuticals

Active, not recruiting

NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

Neuroendocrine Carcinoma | Gastroenteropancreatic Neuroendocrine Tumor | Gastroenteropancreatic Neuroendocrine Neoplasm | Mixed Neuroendocrine-Non Neuroendocrine Neoplasm

United States
University of Pennsylvania
Bristol-Myers Squibb; GlaxoSmithKline

Active, not recruiting

Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy (Parpvax)

Pancreatic Adenocarcinoma

United States
Millennium Pharmaceuticals, Inc.

Terminated

Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma

Melanoma

United States
Bristol-Myers Squibb

Active, not recruiting

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

Unresectable or Metastatic Melanoma

United States, France, Poland, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, Germany, Ireland, Israel, Italy, Netherlands, New Zealand, Norway, Spain, Sweden, Switzerland, United Kingdom, Russian Federation
Yale University

Terminated

A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes

Metastatic Melanoma

United States
Åslaug Helland
Bristol-Myers Squibb; Oslo University Hospital; Ultimovacs ASA

Active, not recruiting

Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (NIPU)

Cancer | Mesothelioma | Mesotheliomas Pleural | Cancer of Lung | Cancer, Lung | Mesothelioma; Pleura | Mesothelioma; Lung

Norway, Denmark, Sweden, Spain, Australia
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer

Renal Cell Carcinoma

France, Spain, Chile, United States, Argentina, Austria, Czechia, Greece, Italy, Mexico, Poland, Portugal, Romania, Russian Federation
Assistance Publique Hopitaux De Marseille

Terminated

Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients

Non-small Cell Lung Cancer

France
Bristol-Myers Squibb

Recruiting

Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients

Advanced Renal Cell Carcinoma (aRCC)

United States
Herlev and Gentofte Hospital
Bristol-Myers Squibb

Recruiting

Checkpoint Inhibitors and SBRT for mCRPC (CheckPRO)

Prostate Cancer Metastatic | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate Cancer | Prostate Cancer Stage IV

Denmark
The Netherlands Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients (OpACIN)

Stage III Skin Melanoma

Netherlands

Search clinical trials for: nivolumab, ipilimumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations